Bufalin

A cardiotonic steroid isolated from Bufo species toads that potently inhibits ouabain-sensitive Na⁺,K⁺-ATPase activity. Induces apoptosis in various human cell lines such as leukemia HL60 and U937 cells by altering the expression of apoptosis-related genes. Reported to stimulate the activities of p21 activated kinase (PAK) and c-Jun Kinase (JNK) in leukemic cell lines. Induces a transient increase in the expression of Tiam1 mRNA in U937 cell lines (~100 nM). Bufalin also down-regulates gene expression of the intracellular signaling protein 14-3-3 in rat lens, probably a consequence of Na⁺-K⁺-ATPase inhibitors. Reduces the level of topoisomerase II in human leukemia cells.

A cardiotonic steroid isolated from toads of Bufo species that potently inhibits ouabain-sensitive Na⁺,K⁺-ATPase activity (IC₅₀ = 1.4 nM). Induces apoptosis in various human cell lines such as leukemia HL-60 and U937 cells by altering the expression of apoptosis-related genes. Reported to stimulate the activities of p21 activated kinase (PAK) and c-Jun Kinase (JNK) in leukemic cell lines. Induces a transient increase in the expression of Tiam1 mRNA in U937 cell lines (~100 nM). Bufalin also down-regulates gene expression of the intracellular signaling protein 14-3-3 in rat lens, probably a consequence of Na⁺,K⁺-ATPase inhibition. Reduces the level of topoisomerase II in human leukemia cells.

Cell permeable: no

Primary Target
Ouabain-sensitive Na+,K+-ATPase activity

Product does not compete with ATP.

Reversible: no

Target IC₅₀: 1.4 nM against ouabain-sensitive Na+,K+-ATPase activity

Packaged under inert gas

Following reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 3 months at -20°C.

Due to the nature of the Hazardous Materials in this shipment, additional shipping charges may be applied to your order. Certain sizes may be exempt from the additional hazardous materials shipping charges. Please contact your local sales office for more information regarding these charges.

Kurosawa, M., et al. 2000. Am. J. Physiol.278, C500.
Kawazoe, N., et al. 1999. Oncogene 18, 2413.
McGowan, M.H., et al. 1999. J. Pharmacol. Exp. Ther. 289, 1559.
Watabe, M., et al. 1998. Oncogene 16, 779.
Hashimoto, S., et al. 1997. Leuk. Res. 21, 875.
Morris, J.F., et al. 1997. Comp. Biochem. Physiol. A Physiol. 118, 599.
Brownlee, A.A., et al. 1990. Clin. Sci.78, 169.

CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany

Toxicity: Highly Toxic (H)